Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)

Treon Steven P.; Meid Kirsten; Tripsas Christina; Heffner Leonard T.; Eradat Herbert; Badros Ashraf Z.; Xu Lian; Hunter Zachary R.; Yang Guang; Patterson Christopher J.; Gustine Joshua; Castillo Jorge J.; Matous Jeffrey; Ghobrial Irene M.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)

【24h】

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)

机译：威勒莫司的前瞻性，多中心临床试验作为沃尔德斯特罗姆癌症癌的主要疗法（WMCTG 09-214）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Everolimus inhibits mTOR, a component of PI3K/ AKT prosurvival signaling triggered by MYD88 and CXCR4-activating mutations in Waldenstrom macroglobulinemia.

机译：目的：艾莫姆斯抑制MTOR，PI3K / AKT刺激信号的组分，由MyD88和Waldenstrom癌症癌血症血症中的CXCR4激活突变引发。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2017年第10期|共5页
作者
Treon Steven P.; Meid Kirsten; Tripsas Christina; Heffner Leonard T.; Eradat Herbert; Badros Ashraf Z.; Xu Lian; Hunter Zachary R.; Yang Guang; Patterson Christopher J.; Gustine Joshua; Castillo Jorge J.; Matous Jeffrey; Ghobrial Irene M.;
展开▼
作者单位

Dana Farber Canc Inst Bing Ctr Waldenstroms Macroglobulinemia Boston MA 02115 USA;

Dana Farber Canc Inst Bing Ctr Waldenstroms Macroglobulinemia Boston MA 02115 USA;

Dana Farber Canc Inst Bing Ctr Waldenstroms Macroglobulinemia Boston MA 02115 USA;

Emory Univ Sch Med Winship Canc Inst Atlanta GA USA;

Univ Calif Los Angeles Jonsson Comprehens Canc Ctr Sch Med Los Angeles CA 90024 USA;

Univ Maryland Greenebaum Canc Ctr Baltimore MD 21201 USA;

Dana Farber Canc Inst Bing Ctr Waldenstroms Macroglobulinemia Boston MA 02115 USA;

Dana Farber Canc Inst Bing Ctr Waldenstroms Macroglobulinemia Boston MA 02115 USA;

Dana Farber Canc Inst Bing Ctr Waldenstroms Macroglobulinemia Boston MA 02115 USA;

Dana Farber Canc Inst Bing Ctr Waldenstroms Macroglobulinemia Boston MA 02115 USA;

Dana Farber Canc Inst Bing Ctr Waldenstroms Macroglobulinemia Boston MA 02115 USA;

Dana Farber Canc Inst Bing Ctr Waldenstroms Macroglobulinemia Boston MA 02115 USA;

Rocky Mt Canc Ctr Denver CO USA;

Dana Farber Canc Inst Bing Ctr Waldenstroms Macroglobulinemia Boston MA 02115 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214) [J] . Treon Steven P., Meid Kirsten, Tripsas Christina, Clinical cancer research: an official journal of the American Association for Cancer Research . 2017,第10期

机译：威勒莫司的前瞻性，多中心临床试验作为沃尔德斯特罗姆癌症癌的主要疗法（WMCTG 09-214）
2. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenstrom Macroglobulinemia [J] . Castillo Jorge J., Meid Kirsten, Gustine Joshua N., Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第14期

机译：Ixazomib，Dexamethasone和Rituximab的前瞻性临床试验作为沃尔德斯特罗姆癌胰岛血症的主要疗法
3. Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting [J] . Abeykoon Jithma Prasad, Zanwar Saurabh, Ailawadhi Sikander, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：Waldenstrom患者的Ibrutinib治疗癌症癌症患者：临床试验环境之外的结果
4. Prospective Multicenter Trial of Gastric Cancer Surgery - A Contribution to Clinical Research on Quality Control [C] . F. Meyer, L. Meyer L, H. Lippert, International Gastric Cancer Congress . 2005

机译：胃癌外科预期多中心试验 - 对质量控制临床研究的贡献
5. Cerebrospinal fluid diversion and intrathecal pressure monitoring in the setting of acute spinal cord injury: A multicenter prospective randomized control trial. [D] . Anthony, Michael P. 2013

机译：急性脊髓损伤情况下的脑脊液转移和鞘内压监测：一项多中心前瞻性随机对照试验。
6. Primary Therapy of Waldenström Macroglobulinemia With Bortezomib Dexamethasone and Rituximab: WMCTG Clinical Trial 05-180 [O] . Steven P. Treon, Leukothea Ioakimidis, Jacob D. Soumerai, -1

机译：硼替佐米地塞米松和利妥昔单抗对华氏巨球蛋白血症的主要治疗：WMCTG临床试验05-180
7. Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248 [O] . Steven P. Treon, Zachary R. Hunter, Jeffrey Matous, 2007

机译：多中心临床试验在复发/难治性Waldenstrom的癌症癌症中的Macroglobulinemia：WMCTG试验结果03-248
8. Coordinating Center Models Project: A Study of Coordinating Centers in Multicenter Clinical Trials. VI. Phases of a Multicenter Clinical Trial [R] . 1979

机译：协调中心模型项目：多中心临床试验中的协调中心研究。 VI。多中心临床试验的阶段

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)

摘要

著录项

相似文献

相关主题

期刊订阅